Introduction. Deep venous thrombosis (DVT) is a potentially serious complication after total hip (THA) and knee (TKA) arthroplasty, traditionally justifying aggressive prophylaxis with low molecular weight heparin (LMWH) or direct oral anticoagulants (DOA) at the cost of an increased risk of bleeding. However, fast-track procedures might reduce the DVT risk and decrease the cost-benefit ratio of the current recommendations. The objective of this study was to compare thrombotic and bleeding risk in an unselected population of elective THA and TKA with a fast-track procedure. MATERIAL - METHODS. A series of 1,949 patients were analyzed prospectively. There were 1,136 women and 813 men, with a mean age of 70 years. In particular, 16% were previously treated by antiplatelet agents and 8% by anticoagulants. All patients followed a fast-track procedure including early walking within 24 hours of surgery, and 80% of patients returned home after surgery, with a mean length of stay of 3 days (THA) or 4 days (TKA). The occurrence of a thromboembolic event or hemorrhagic complication has been identified. Results. Out of the 1,110 THAs, 5 thromboembolic events were identified (0.4%): 2 non-fatal pulmonary embolism and 3 DVTs. There was no impact of these complications on the final result. 19 hemorrhagic complications were identified (1.7%): 10 significant haematomas (3 of which were complicated by infection), 9 anemias (with 4 transfusions). Out of the 839 TKAs, 9 thromboembolic events were identified (1.0%): 4 non-fatal pulmonary embolism and 5 DVTs. There was no impact of these complications on the final result. 14 hemorrhagic complications were identified (1.7%): 8 haematomas including 4 reoperations, 6 anemias (with 5 transfusions). Discussion. Thromboembolic complications after elective THA and TKA have virtually disappeared, with a rate of 0.7%. On the other hand, bleeding complications are now more frequent, with a rate of 1.7%. This suggests that the cost-benefit ratio of preventive treatments with LMWH or DOA should be reassessed. Prescribing LMWH or DOA after elective THA and TKA with fast-track procedures exposes the patient to a much higher risk of bleeding than thrombotic risk. The use of aspirin may represent an acceptable compromise in these patients

A wide variety of hospital data is reported to and published by national groups intending to compare quality of care between institutions. The rate of deep venous thrombosis and pulmonary embolism (DVT/PE) after orthopaedic surgery is among those reported. In an effort to examine the validity of hospital data reported to these national groups, we looked deeper into the cases of DVT reported by our hospital to the University Health Services Consortium (UHC). The rate of DVT/PE after orthopaedic surgical procedures reported to UHC for 2007 was 2.6% (33 cases). This rate is over twice the UHC mean for this same time period. Review of the 33 reported cases of DVT/PE revealed that only 12 were appropriately coded; if appropriately coded and reported, the DVT/PE rate would have been 0.95%. The rates of DVT/PE reported by this institution to UHC result in that institution being characterised as having comparatively high rates of this complication. However, the validity of this characterisation should be questioned, based on inconsistencies seen in the institution's diagnostic coding. This investigation raises concerns that coding variations between institutions may prohibit accurate quantification of hospital complications and ought not be used for the purpose of benchmarking

Background. Post-operative deep venous thrombosis (DVT) and subsequent pulmonary embolism (PE) remain a serious complication after total joint replacement. Although with modern chemical and mechanical prophylaxis and rapid rehabilitation the rate of symptomatic DVT and PE has reduced, isolation of pre-operative DVT, specially in patients with prior history of DVT remains a challenge. The aim of this study was to assess the use of pre-operative dopplers as a tool to detect and identify prior DVT in patients undergoing total joint replacement. Methods. Between January 2014 and December 2014, 211 elective primary and revision hip and knee arthroplasty were identified from our prospective institutional database. All cases were performed by two adult reconstruction specialists. All primary total hip arthroplasties (THA) were non-cemented and all primary total knee arthroplasties (TKA) were cemented with similar implant and technique. Prior to July 2014, only patients with prior history of DVT or PE underwent pre-operative dopplers. From July 2014, all cases underwent routine pre-operative doppler screening. All patients with clinical symptoms of calf pain underwent post-operative dopplers. Patients were followed for a minimum of 3 month post-operatively. All emergency room (ER) visits for role out DVT were identified. No patient was lost to follow. Results. 115 patients patient underwent pre-operative dopplers. Three patients had a history of prior popliteal DVT, none of which had post-operative DVT or PE. In the remaining 112 patients, none of the pre-operative dopplers were positive for DVT. 34 patients in this group (29%) underwent post-operative dopplers, either during the hospital stay or in the ER within 3 month after index surgery. Only one patient developed symptomatic PE (0.8%) after total knee arthroplasty. 96 patients did not have pre-operative dopplers, 3 of which (3%) had symptomatic DVT and PE during hospital stay, all after total knee arthroplasty. There was no statistical difference for rate of symptomatic DVT/PE between the two groups (p=0.3). There was no correlation between DVT and obesity, age, or revision versus primary cases. Discussion and Conclusions. Routine pre-operative dopplers do not significantly lower rate of symptomatic DVT/PE and are not helpful in early detection and prevention in asymptomatic patients prior to routine total joint replacement

Background. Post-operative deep venous thrombosis (DVT) and subsequent pulmonary embolism (PE) remain a serious complication after total joint replacement. Although with modern chemical and mechanical prophylaxis and rapid rehabilitation the rate of symptomatic DVT and PE has reduced, isolation of pre-operative DVT, especially in patients with prior history of DVT remains a challenge. The aim of this study was to assess the utility of pre-operative dopplers as a tool to screen and reduce DVT/PE rate in patients undergoing total joint replacement. Methods. Between January 2014 and December 2014, 211 elective primary hip and knee arthroplasty were identified from our prospective institutional database as two consecutive cohorts (115 cases had pre-operative dopplers and 96 did not). All cases were performed by two adult reconstruction specialists. All primary total hip arthroplasties (THA) were non-cemented and all primary total knee arthroplasties (TKA) were cemented with similar implant and technique. In the first cohort, all cases underwent routine pre-operative doppler screening and in the control cohort, only patients with prior history of DVT or PE underwent pre-operative dopplers. All patients with clinical symptoms of calf pain underwent post-operative dopplers. Patients were followed for a minimum of 3 month post-operatively. All emergency room (ER) visits for role out DVT were identified. No patient was lost to follow. Results. In the cohort with pre-operative dopplers, none of the pre-operative dopplers were positive for DVT, including three patients that had a history of prior DVT. 34 patients in this group (29%) underwent post-operative dopplers, either during the hospital stay or in the ER within 3 month after index surgery. Only one patient (no prior history of DVT) developed symptomatic DVT/PE (0.8%) after total knee arthroplasty. In the control cohort, 3 of which (3%) had symptomatic DVT, one of which had PE (1%) during hospital stay, all after total knee arthroplasty. There was no statistical difference for rate of symptomatic DVT/PE between the two groups (p=0.3). There was no correlation between DVT and age, gender or BMI. Discussion and Conclusions. Utilization of routine pre-operative dopplers for all patients did not lower the rate of symptomatic DVT/PE and are not helpful in early detection and prevention in asymptomatic patients prior to routine total joint replacement. Pre-operative dopplers should be used in selected patients with high risk of DVT

Patients with a thrombotic history are thought to be at greater risk for developing blood clots following total hip arthroplasty (THA) or total knee arthroplasty (TKA). The incidence of venous thromboembolism and risk factors associated with clot development in this population of patients, however, are not well defined. From the years 2002 to 2008, 547 patients undergoing elective joint arthroplasty with a history of thrombotic disease, defined by prior history of deep venous thrombosis (DVT) or pulmonary embolism (PE), were followed prospectively for a minimum of one month after TKA or THA. Patients received prophylactic anticoagulation with coumadin starting on POD 1 with or without bridge therapy with low molecular weight heparin (LMWH). Patients were compared for the following risk factors: advanced age (> 70 years old), inherited or acquired thrombophilia, time elapsed since prior episode, association of prior episode with surgery, and method of anticoagulation. Of the 547 patients, 72 (13.2%) developed symptoms consistent with DVT or PE. Thirty-two thromboembolic events (5.9%, 26 DVT, 6 PE) were confirmed by lower extremity Doppler ultrasound, spiral computerized tomography or ventilation-perfusion scanning. 60% of events occurred before POD 3, and the average INR at the time of diagnosis was 1.67. The incidence of thromboembolism was 14.6% and 9.9% for unilateral TKA and THA, respectively and 27.6% and 25% for bilateral TKA and THA, respectively. The institutional rate of DVT during that same time frame is 1.9%. History of inherited or acquired thrombophilia (p< 0.01), time elapse since prior thrmoboembolic event (p=0.04), and association of prior events with surgery (p=0.02) significantly increase the risk of thromboembolism in this population. Bridge therapy with LMWH of any dose did not significantly reduce the risk of DVT or PE, however, there was a trend towards significance (p=0.17). Eight patients (1.5%) experienced bleeding complications; 6 were major in nature (gastrointestinal bleeding and joint hematoma). Patients with a thrombotic history are at increased risk for developing DVTs after joint arthroplasty. These patients share the same risk factors for development of DVT or PE then patients without a history of prior events. Furthermore, thromboembolic events tend to occur early following surgery in these patients and treatment with LMWH may help reduce the risk of developing clots when used in combination with coumadin

Aim of Study: To assess the efficacy of Computerised Strain Gauge Plethysmography (CSGP) to screen for proximal Deep Venous Thrombosis (DVT) following Total Knee Replacement (TKR). Introduction: CSGP is a non invasive, bedside screening tool, used to detect the presence of proximal lower limb DVT. CSGP uses a low pressure thigh cuff to first occlude venous outflow. When the cuff is released the device is used to measure changes in calf dimensions (by means of strain gauges tied around a standardised point of the calf of the patient’s operated limb) thereby giving a measure of venous outflow. Obstruction to outflow (producing a positive result with the device) is seen with occlusion of proximal veins. Patients & Methods: A retrospective analysis of 184 consecutive patients who had undergone primary TKR was performed. Foot pumps were used for thrombophylaxis during the erioperative period. On the fifth post operative day all patients were screened for proximal DVT using CSGP. Those with a negative result who were ambulating safely were discharged. Those with a positive test had further imaging to confirm or refute the diagnosis of proximal DVT in the operated limb. The patients’ medical notes were scrutinised for evidence of re attendances and evidence of whether proximal DVT was diagnosed following discharge from the ward. Results: The negative predictive value of CSGP was found to be 99%. The sensitivity of CSGP for detecting proximal DVT was 83 %. The specificity was found to be 69%. The false positive rate was 92%. Conclusion: CSGP allows the safe and prompt discharge of TKR patients who testnegative with CSGP with some degree of confidence. Patients who test positive with CSGP however require further imaging to select out those individuals who have clinically significant proximal DVT meriting full anticoagulation post operatively

The selection of a prophylaxis agent is a balance between efficacy and safety. Total knee arthroplasty patients receive DVT prophylaxis because orthopaedic surgeons are concerned about the morbidity and mortality associated with pulmonary embolism. However, at the same time there is great concern about excessive bleeding. The goal is to provide the appropriate anticoagulation to prevent symptomatic pulmonary embolism (PE) and DVT but at the same time avoid over anticoagulation which can be associated with bleeding and other wound problems. Therefore, risk stratification is necessary.

Although risk stratification is the ideal way to determine the appropriate prophylaxis agent to use for a specific patient, there is no validated risk stratification strategy available today. There is general agreement at this time that patients who have had a prior PE or symptomatic DVT are at higher risk for development of a pulmonary embolism. In addition, there is a general belief that patients who have coagulation abnormalities (i.e. Factor V Leiden, Protein C and S deficiency) have an increased risk of developing a pulmonary embolism. Other factors that have been mentioned as associated with PE after total hip arthroplasty include age, female gender, and higher body mass index. The selection of a prophylaxis regimen should be influenced by the ability to mobilise the patient after surgery.

Introduction: Risk-profiling of patients in knee arthroplasty to prepare for postoperative complications is becoming more important. Materials and Methods: Major complications (hematoma, cardio-vascular complication, deep venous thrombosis, pulmonary embolism, joint infection and pneumonia) following 17644 knee arthroplasties occurring within the postoperative hospitalization period have been documented based on a standardized protocol used for external quality assessment in Germany. Using logistic regression, the influence of potential risk factors were assessed for their significance on postoperative complications and uni-variate analysis used to assess this influence on every single major complication. The influence of patient age and the surgery time on major complications were calculated using ANOVA. Results: Major postoperative complications occurred in 7.22 per cent with hematoma in 2.89, cardio-vascular complications in 1.79, deep venous thrombosis in 1.23, pulmonary embolism in 0.23, joint infection in 0.82 and pneumonia in 0.25 per cent. Patient age, surgery time, gender, high classification according to the American Association of Anesthesiologists, allogeneic blood transfusion and lateral release significantly increased the rate of postoperative complications. Males are more prone to suffer from hematoma, joint infection and pneumonia in the immediate postoperative course. Females are more endangered for deep venous thrombosis. Extended surgery time increased the rate of hematoma and infection, increased patient age elevated the rate of hematoma, cardiovascular complication and pneumonia. Alloge-neic blood transfusion increased the risk of all major complications except deep venous thrombosis. Conclusions Male gender, allogeneic blood transfusion, increased age and surgery time elevate immediate postoperative complications following knee arthroplasty

Purpose: The purpose of this study was to determine the rate of clinically detected deep venous thrombosis and pulmonary embolism in patients with trunk or extremity bone or soft tissue sarcomas. Patients and methods: The clinical records of patients with a confirmed diagnosis of primary bone or soft tissue sarcoma presenting between 1998 and 2003 were reviewed. Data relating to clinical features, risk factors for thromboembolism and clinical thromboembolic events were retrieved. Results: 252 patients were identified. 94 had a diagnosis of primary bone sarcoma and 158 a diagnosis of primary soft tissue sarcoma. The mean age was 53 (range 15 to 94); 137 (54%) were male. 37 patients were suspected clinically of having a deep venous thrombosis, 10 of which were confirmed radiologically, giving a rate of 4%. Nine patients had a suspected pulmonary embolism, 2 of which were confirmed radiologically and one of whom died of pulmonary embolism, giving an overall rate of fatal pulmonary embolism of 0.4%. All patients with thromboembolic events had lower extremity tumours and all were surgical patients. However, the majority of thromboembolic events (6 of 10 deep venous thromboses and 2 of 3 pulmonary embolisms) occurred prior to surgery. Discussion: The risk of a clinically apparent thromboembolic event in patients with bone or soft tissue sarcomas is comparable to that in other orthopaedic patients. Risk factors for venous thromboembolism include lower extremity sarcomas and mechanical obstruction of the venous system. Consideration should be given to excluding deep venous thrombosis before surgery

Introduction: Risk-profiling of patients in hip arthroplasty to prepare for perioperative complications is becoming more important. Materials and Methods Major complications (haematoma, cardiovascular complication, deep venous thrombosis, pulmonary embolism, joint infection, injuries of neurovascular structures and pneumonia) following 29994 hip arthroplasties occurring within the postoperative hospitalisation period have been documented based on a standardised protocol used for external quality assessment in Germany. Using logistic regression, the influence of potential risk factors was assessed for their significance on postoperative complications and univariate analysis was used to assess this influence on every single major complication. The influence of patient age and the surgery time on major complications were calculated using ANOVA. Results: Major perioperative complications occurred in 7,26 per cent. Haematomas were reported in 3.22, cardiovascular complications in 1.55, joint infections in 0.94, injuries of neuro-vascular structures in 0,63, deep venous thrombosis in 0.37, pulmonary embolism in 0.26 and pneumonia in 0.28 per cent of all cases. Patient age, length of surgery and allogeneic blood transfusion significantly increased the rate of major perioperative complications. Increased patient age increased the risk for all major complications but neuro-vascular injuries. Increased surgery time elevated the risk for all major complications except haematoma. Allogeneic blood transfusions were associated with an elevated risk for all major postoperative complications except deep venous thrombosis. In contrast, autologous blood transfusions did not increase the risk for suffering a postoperative complication. Surprisingly, gender did not have a significant influence on the occurrence of immediate postoperative complications. Conclusions Allogeneic blood transfusion, increased age and surgery time contribute to an elevated incidence of perioperative complications following hip arthroplasty

Venous thromboembolic events, either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty. The purpose of this study was to evaluate the effectiveness of a mobile compression device (ActiveCare+S.F.T.®; Medical Compression Systems, Inc., Or Akiva, Israel) with or without aspirin compared with current pharmacology protocols for venous thromboembolism prophylaxis in patients undergoing elective primary unilateral lower extremity joint arthroplasty. A multicenter registry was established to capture the rate of symptomatic venous thromboemboli following primary lower extremity joint arthroplasty in 3,060 patients from ten sites including knee arthroplasty (1,551) or hip arthroplasty (1,509). All patients were 18 years of age or older with no known history of venous thromboembolism, coagulation disorder, or solid tumor. Use of the compression device began peri-operatively and continued for a minimum of ten days. Patients with symptoms of deep venous thrombosis or pulmonary embolism underwent duplex ultrasonography and/or spiral computed tomography. All patients were evaluated at three months post-operatively to document any evidence of deep venous thrombosis or pulmonary embolism. Of 3,060 patients, twenty-eight (0.92%) had venous thromboembolism (20 distal deep venous thromboses, 3 proximal deep venous thromboses, and 5 pulmonary emboli). One death occurred with no autopsy performed. Symptomatic venous thromboembolic rates observed in lower extremity joint arthroplasty patients using the mobile compression device were non-inferior (not worse than) at a margin of 1.0% to rates reported for pharmacological prophylaxis, including warfarin, enoxaparin, rivaroxaban, and dabigatran except in the knee arthroplasty group where the mobile compression device fell short of rivaroxaban by 0.06%. Use of the mobile compression device with or without aspirin for patients undergoing lower extremity joint arthroplasty provide a non-inferior risk for developing venous thromboembolism compared with current pharmacological protocols reported in the literature

Venous thromboembolic events, either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty. The purpose of this study was to evaluate the effectiveness of a mobile compression device (ActiveCare+S.F.T.®; Medical Compression Systems, Inc., Or Akiva, Israel) with or without aspirin compared with current pharmacology protocols for venous thromboembolism prophylaxis in patients undergoing elective primary unilateral lower extremity joint arthroplasty. A multicenter registry was established to capture the rate of symptomatic venous thromboemboli following primary lower extremity joint arthroplasty in 3,060 patients from ten sites including knee arthroplasty (1,551) or hip arthroplasty (1,509). All patients were eighteen years of age or older with no known history of venous thromboembolism, coagulation disorder, or solid tumor. Use of the compression device began perioperatively and continued for a minimum of ten days. Patients with symptoms of deep venous thrombosis or pulmonary embolism underwent duplex ultrasonography and/or spiral computed tomography. All patients were evaluated at three months postoperatively to document any evidence of deep venous thrombosis or pulmonary embolism. Of 3,060 patients, 28 (0.92%) had venous thromboembolism (20 distal deep venous thromboses, 3 proximal deep venous thromboses, and 5 pulmonary emboli). One death occurred with no autopsy performed. Symptomatic venous thromboembolic rates observed in lower extremity joint arthroplasty patients using the mobile compression device were non-inferior (not worse than) at a margin of 1.0% to rates reported for pharmacological prophylaxis, including warfarin, enoxaparin, rivaroxaban, and dabigatran except in the knee arthroplasty group where the mobile compression device fell short of rivaroxaban by 0.06%. Use of the mobile compression device with or without aspirin for patients undergoing lower extremity joint arthroplasty provide a non-inferior risk for developing venous thromboembolism compared with current pharmacological protocols reported in the literature

Venous thromboembolic events, either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty. The purpose of this study was to evaluate the effectiveness of a mobile compression device (ActiveCare+S.F.T.®; Medical Compression Systems, Inc., Or Akiva, Israel) with or without aspirin compared with current pharmacology protocols for venous thromboembolism prophylaxis in patients undergoing elective primary unilateral lower extremity joint arthroplasty. A multicenter registry was established to capture the rate of symptomatic venous thromboemboli following primary lower extremity joint arthroplasty in 3,060 patients from ten sites including knee arthroplasty (1,551) or hip arthroplasty (1,509). All patients were eighteen years of age or older with no known history of venous thromboembolism, coagulation disorder, or solid tumor. Use of the compression device began peri-operatively and continued for a minimum of ten days. Patients with symptoms of deep venous thrombosis or pulmonary embolism underwent duplex ultrasonography and/or spiral computed tomography. All patients were evaluated at three months post-operatively to document any evidence of deep venous thrombosis or pulmonary embolism. Of 3,060 patients, twenty-eight (0.92%) had venous thromboembolism (twenty distal deep venous thromboses, three proximal deep venous thromboses, and five pulmonary emboli). One death occurred with no autopsy performed. Symptomatic venous thromboembolic rates observed in lower extremity joint arthroplasty patients using the mobile compression device were non-inferior (not worse than) at a margin of 1.0% to rates reported for pharmacological prophylaxis, including warfarin, enoxaparin, rivaroxaban, and dabigatran except in the knee arthroplasty group where the mobile compression device fell short of rivaroxaban by 0.06%. Use of the mobile compression device with or without aspirin for patients undergoing lower extremity joint arthroplasty provide a non-inferior risk for developing venous thromboembolism compared with current pharmacological protocols reported in the literature

Venous thromboembolic events, either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty. The purpose of this study was to evaluate the effectiveness of a mobile compression device (ActiveCare+S.F.T.®; Medical Compression Systems, Inc., Or Akiva, Israel) with or without aspirin compared with current pharmacology protocols for venous thromboembolism prophylaxis in patients undergoing elective primary unilateral lower extremity joint arthroplasty. A multicenter registry was established to capture the rate of symptomatic venous thromboemboli following primary lower extremity joint arthroplasty in 3,060 patients from ten sites including knee arthroplasty (1,551) or hip arthroplasty (1,509). All patients were eighteen years of age or older with no known history of venous thromboembolism, coagulation disorder, or solid tumor. Use of the compression device began perioperatively and continued for a minimum of ten days. Patients with symptoms of deep venous thrombosis or pulmonary embolism underwent duplex ultrasonography and/or spiral computed tomography. All patients were evaluated at three months postoperatively to document any evidence of deep venous thrombosis or pulmonary embolism. Of 3,060 patients, twenty-eight (0.92%) had venous thromboembolism (twenty distal deep venous thromboses, three proximal deep venous thromboses, and five pulmonary emboli). One death occurred with no autopsy performed. Symptomatic venous thromboembolic rates observed in lower extremity joint arthroplasty patients using the mobile compression device were non-inferior (not worse than) at a margin of 1.0% to rates reported for pharmacological prophylaxis, including warfarin, enoxaparin, rivaroxaban, and dabigatran except in the knee arthroplasty group where the mobile compression device fell short of rivaroxaban by 0.06%. Use of the mobile compression device with or without aspirin for patients undergoing lower extremity joint arthroplasty provides a non-inferior risk for developing venous thromboembolism compared with current pharmacological protocols reported in the literature

Introduction. The incidence of deep venous thrombosis (DVT) in patients with lower limb cast immobilization occurs in up to 20% of patients. This may result from altered calf pump function causing venous stasis. Our aim was to determine the effects of below knee cast on calf pump function. Method. Nine healthy participants were enrolled in this research and ethics approved prospective study. Four foot and ankle movements (toe dorsiflexion, toe plantar flexion, ankle dorsiflexion, ankle plantar flexion) and weight bearing were performed pre and post application of a below knee cast. Baseline and peak systolic velocity within the popliteal vein was measured during each movement. Participants with peripheral vascular disease, varicose veins, deep venous thrombosis or previous foot and ankle surgery were excluded. Results. The mean patient age was 34 years (range 28–58), the majority were female (n = 6). With cast in situ all movements resulted in a statistically significant increase in peak systolic velocity (p = <0.05). There was no significant difference in peak systolic velocity at the popliteal vein pre or post cast application. Discussion. This is the first study to examine the effect of a lower limb cast on calf muscle pump function. Despite cast immobilisation, toe and ankle flexion and extension movements significantly increase peak systolic velocity measured at the popliteal vein. Conclusion. Toe and ankle flexion and extension exercises significantly increase calf pump function in patients with below knee cast immobilization. We recommend that all patients treated in below knee cast immobilisation are advised to perform regular toe and ankle exercises to reduce venous stasis and risk of deep venous thromboembolism

Introduction. The muscles of the leg collectively comprise the calf pump, however the action of each muscle group on calf pump function is not known. Patients with foot or ankle injury or surgery are often advised to perform foot and ankle movements to help prevent deep venous thrombosis. Our aim was to determine which foot and ankle movements were most effective in stimulating the calf pump. Method: Nine healthy participants were enrolled in this research and ethics approved prospective study. Participants with a previous history of peripheral vascular disease, varicose veins, deep venous thrombosis or previous foot and ankle surgery were excluded. Each participant followed a standardized protocol of foot and ankle movements, starting with foot in neutral position and the baseline and movement peak systolic velocity within the popliteal vein was measured during each movement. The movements tested were toe dorsiflexion, toe plantar flexion, ankle dorsiflexion, ankle plantar flexion. Results. The mean patient age was 34 years (range 28–58), the majority were female (n = 6). All movements resulted in statistically significant changes in peak systolic velocity (p = <0.05). In order of decreasing peak velocity the exercises which had greatest effect on calf pump function were: Ankle dorsiflexion (101cm/s), Ankle plantarflexion (84cm/s), Toe dorsiflexion (63cm/s), Toe plantarflexion (59cm/s). We have shown that all four exercises significantly increased calf pump function. The greatest effect was seen with ankle movements. Conclusion. Toe and ankle flexion and extension exercises significantly increase calf pump function and should be advised for all patients following foot or ankle injury and surgery as this may reduce venous stasis and risk of venous thromboembolism

Introduction: Several institutes in continental Europe and the US now prescribe low molecular weight heparin for patients with ankle fractures being treated in a below knee plaster cast. Jorgensen et al reported an incidence of deep venous thrombosis (DVT) of up to 20% in patients treated in a cast. However, their study included patients with variable diagnoses, ranging from tendon ruptures to fractures. The aim of our study was to assess the incidence of DVT in patients with ankle fractures that have been treated conservatively in a below knee cast. Method: We performed an ultrasound scan on patients with conservatively ankle fractures at the time of removal of the cast. The same ultrasound technician performed all the scans. The local regional ethics committee had approved this study. Results: So far we have performed an ultrasound scan on 98 patients with ankle fractures. We are likely to complete the study in November 2006 (120 patients). We have encountered only 2 below knee DVTs (2.04 %). None of them involved the popliteal vein. Both patients were completely asymptomatic and were full weight bearing in the cast. A repeat scan showed no evidence of progression. None of the patients had an above knee DVT or a pulmonary embolism. Discussion: The risk of deep venous thrombosis is said to be higher in patients with a plaster cast because of the decreased ability of the calf muscles to pump the venous blood back to the heart. Though some studies have indicated an incidence of up to 20%, the incidence in our population was only about 2%Thus, DVT is a rare event in patients with ankle fractures. Though it is a serious event, its rarity does not justify a blanket prophylaxis regimen for all patients with ankle fractures

Introduction: Deep Venous Thrombosis (DVT) and pulmonary embolism (PE) cause significant morbidity and mortality in orthopaedic surgical practice, although the incidence following surgery to the lumbosacral spine is less than following lower limb surgery. Our objective was to compare our rate of thromboembolic complications with those published elsewhere and investigate whether the adoption of additional pharmacological and physical measures had reduced the incidence of clinically evident deep venous thrombosis (DVT) and pulmonary embolism (PE). Materials and Method: This study was undertaken to investigate the incidence of DVT/PE during the 10 years from 1/1/1985 to 31/12/1994, and then to assess the effectiveness of an anticoagulant policy introduced during 1995 using low dose aspirin or LMH in high risk cases. All records for spinal operations were reviewed for thromboembolic complications by reference to the Scottish Morbidity Record form SMR1. To ensure that all patients were compliant with the policy, data for the whole of 1995 was omitted and the period 1/1/1996 to 31/12/2003 was taken to assess its effectiveness. Surgery was done with the patient in the kneeling, seated prone position which leaves the abdomen free and avoids venous kinking in the legs. Results: Records of a total of 1111 lumbar spine operations were performed from 1/1/1985 to 31/12/2004 were reviewed. The overall incidence of thromboembolic complications was 0.29%. A total of 697 operations were performed from 1/1/1985 to 311994 with two cases of DVT and no cases of PE giving thromboembolic complication rate of 0.29%. During the period 1/1/1996 to 31/12/2003, 414 operations resulted in one case of DVT and no cases of PE, a rate 0f 0.24%. Conclusion: The incidence of thromboembolic complications is low whether or not anticoagulation is used. We believe that the kneeling, seated prone operating position is a significant contributing factor

Deep venous thrombosis (DVT) and clinical outcome measurements in a series of 610 patients who did not receive routine chemical thromboprophylaxis for lower limb arthroplasty were studied. Patients who had undergone primary total hip or knee replacement under the care of two orthopaedic consultants were identified from the Trent Arthroplasty Database. Surgery was performed between 1992 and 1999 in one hospital only. Venography was undertaken on the seventh to tenth postoperative day. Patients with proximal thrombosis were anti-coagulated with warfarin as per protocol. Venogram reports were available for 81% of cases. One year following surgery a standard postal questionnaire was sent to all patients. A response rate of 88% was achieved. Data was captured with respect to residual pain, ability to walk and the overall satisfaction with joint replacement. DVT following total hip (THR) or knee replacement (TKR) in patients who did not receive routine chemical thromboprophylaxis was common (46. 4%) in line with other studies. Knee surgery was associated with a high prevalence of thrombosis (57. 6%) compared to hip replacement although only one fifth of DVTs were found to extend into a proximal vein. Approximately half (44. 2%) of all THR associated thrombus was above knee DVT. Questionnaire responses evaluating clinical outcome and satisfaction were correlated to venographic results and analysed using an SPSS statistical package. Using Chi-squared analysis no statistically significant differences were found between deep venous thrombosis and patient-perceived pain (p=0. 12), mobility (p=0. 07) or overall satisfaction (p=0. 23). It is generally assumed that chemical thromboprophylaxis will diminish DVT related complications such as post-phlebitic limb syndrome. Despite a high prevalence of thrombosis in patients who did not receive pharmacological agents for prophylaxis, this study did not demonstrate an adverse outcome on pain, function or patient satisfaction. Morbidity as a result of DVT needs to be studied further before the role of chemical thromboprophylaxis can be determined

The Hospital (Trust) guidelines generally recommend 40mg of Low molecular weight heparin (LMWH) twice daily (BD) for all patients over 100kg for those undergoing total hip (THR) and knee replacements (TKR) respectively. British National Formulary (BNF) recommends 40mg of LMWH once daily (OD) for all patients regardless of their overall weight or body mass index (BMI). We evaluated the outcome of prophylactic LMWH dosage for patients undergoing THR and TKR by monitoring surgery related venous-thromboembolic events up to a minimum of three months after surgery. A retrospective audit was carried out after obtaining institutional approval and all consecutive elective patients weighing over 100kg and undergoing THR and TKR were included. All patients were followed up for a minimum of 3 months after their operation to investigate the dose of prophylactic LMWH received, and whether they had developed any venous thromboembolic events (VTE) post operatively. This was done using a combination of electronic notes, drug charts and deep venous thrombosis (DVT) or computed tomography pulmonary angiogram (CTPA) reports on the hospital/trust database. A total of 53 patients underwent elective THR (18) and TKR (35) between the period of March 2017 and September 2017. Forty-four patients received 40 mg OD and 9 patients had 40 mg BD. None of the patients developed a confirmed DVT or pulmonary embolism in the 3 months following surgery regardless of the dose received. We demonstrate that there is no clinical benefit in having patients over 100kg on twice daily LMWH with the aim of preventing post-op thromboembolic complications. This conclusion is in line with the BNF recommendations for VTE prophylaxis